Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crisugabalin besilate - Haisco Pharmaceutical Group

Next Previous
Drug Profile

Crisugabalin besilate - Haisco Pharmaceutical Group

Alternative Names: Hiscoliclagabalin; HSK-16149; Smiphen

Latest Information Update: 09 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Haisco Pharmaceutical Group
  • Class Analgesics; Small molecules; Urologics
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neuropathic pain; Postherpetic neuralgia
  • Phase III Pain
  • Phase II Neuralgia; Postoperative pain
  • No development reported Diabetic neuropathies

Most Recent Events

  • 09 Sep 2026 Chemical structure information added
  • 25 Aug 2026 Phase-III clinical trials in Pain in China (PO) prior to August 2026 (Haisco Pharmaceutical Group pipeline, August 2026)
  • 09 May 2026 NMPA proposes for crisugabalin besilate for Neuropathic pain for priority review

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top